Optimización de la antiagregación en el infarto agudo de miocardio con elevación del segmento ST

Ruiz Nodar, Juan M; Galcerá Jornet, Emilio; Gómez Sansano, Jose María.
Rev. esp. cardiol. Supl. (Ed. impresa) ; 14(supl.A): 24a-31a, 2014. graf, tab
Artículo en Español | IBECS (España) | ID: ibc-165947

Documentos relacionados

  1. Thrombus remodelling by reversible and irreversible P2Y<sub>12</sub> inhibitors.
  2. Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding.
  3. Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
  4. Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.
  5. Patient-tailored antithrombotic therapy following percutaneous coronary intervention.
  6. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications.
  7. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
  8. Long term antithrombotic threapy after myocardial infarction: why, to whom and which one?
  9. Antithrombotic therapy in diabetes: which, when, and for how long?
  10. Antithrombotic Therapy after Acute Coronary Syndromes. Reply.